Valby, Denmark, 2015-11-30 15:24 CET (GLOBE NEWSWIRE) -- In accordance with Section 6 of the Danish Statutory Order on Issuers’ Disclosure Obligations, H. Lundbeck A/S is required to publish the total number of voting rights and the size of the share capital in H. Lundbeck A/S as per the end of a month where changes therein have occurred.
Referring to Corporate Release no 572 dated 17 November 2015, please find below a statement regarding the total number of voting rights and share capital in H. Lundbeck A/S as per 30 November 2015.
|
Number of shares (nominal value DKK 5) |
Nominal value (DKK) |
Number of votes | |
| Shares | 197,301,281 | 986,506,405 | 197,301,281 |
Lundbeck contacts
| Investors: | Media: |
| Palle Holm Olesen | Mads Kronborg |
| Vice President, Investor Relations | Director, Corporate Communication |
| PALO@lundbeck.com | MAVK@lundbeck.com |
| +45 36 43 24 26 | +45 36 43 30 00 |
About Lundbeck
Lundbeck (LUN.CO, LUN DC, HLUYY) is a global pharmaceutical company specialized in brain diseases. For more than 70 years, we have been at the forefront of research within neuroscience. Our key areas of focus are Alzheimer’s disease, depression, Parkinson’s disease and psychosis.
An estimated 700 million people worldwide are living with brain disease and far too many suffer due to inadequate treatment, discrimination, a reduced number of working days, early retirement and other unnecessary consequences. Every day, we strive for improved treatment and a better life for people living with brain disease – we call this Progress in Mind.
Our approximately 5,500 employees in 57 countries are engaged in the entire value chain throughout research, development, production, marketing and sales. Our pipeline consists of several late-stage development programmes and our products are available in more than 100 countries. We have research centres in China and Denmark and production facilities in China, Denmark, France and Italy. Lundbeck generated core revenue of DKK 13.5 billion in 2014 (EUR 1.8 billion; USD 2.4 billion).
For additional information, we encourage you to visit our corporate site www.lundbeck.com and connect with us on Twitter at @Lundbeck.
